T005 HHSN26100005 TORFP 2017-E04 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Evaluation of "Clinical-Ready" Agents (Bazedoxifene and Lapatinib) in Combination for the Prevention of ER+ and ER- Mammary Cancers

Grant

Date/time Interval

  • September 15, 2015 - September 16, 2021
  • Total Award Amount

  • 767562.00
  • Direct Costs

  • 516877.00
  • Sponsor Award Id

  • HHSN261201500036I-HHSN26100005
  • Contributor

  • Grubbs Ph.D., Clinton   Principal Investigator